SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0000950170-23-063774
Filing Date
2023-11-14
Accepted
2023-11-14 16:31:45
Documents
13
Period of Report
2023-09-29
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A sabs-20230929.htm   iXBRL 8-K/A 54864
  Complete submission text file 0000950170-23-063774.txt   211994

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sabs-20230929_def.xml EX-101.DEF 13849
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sabs-20230929.xsd EX-101.SCH 3214
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sabs-20230929_pre.xml EX-101.PRE 13149
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sabs-20230929_lab.xml EX-101.LAB 17768
7 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20230929_htm.xml XML 6938
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39871 | Film No.: 231407063
SIC: 2836 Biological Products, (No Diagnostic Substances)